Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27237496 | 0.95 | MEN1 (0.66) | MEN1KMT2ASMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL7502088 | 0.84 | CYP4F2 (0.56) | MEN1KMT2ASMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL22504144 | 0.83 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2L3MBTL1EPHX2 | |
| SCHEMBL1940297 | 0.83 | POLB (0.62) | MEN1KMT2ASMN1; SMN2NLRP3EPHX2 | |
| SCHEMBL19730987 | 0.83 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2NLRP3EPHX2 | |
| SCHEMBL7983265 | 0.82 | POLB (0.56) | MEN1KMT2ASMN1; SMN2NLRP3EPHX2 | |
| SCHEMBL13329837 | 0.81 | NLRP3 (0.57) | MEN1KMT2ASMN1; SMN2L3MBTL1NLRP3 | |
| SCHEMBL4113212 | 0.81 | CYP4F2 (0.76) | KMT2ASMN1; SMN2CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL378549 | 0.81 | VNN1 (0.52) | MEN1KMT2ASMN1; SMN2MRGPRX4VNN1 | |
| SCHEMBL378766 | 0.80 | EPHX2 (0.54) | MEN1KMT2ASMN1; SMN2NLRP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774805-B1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER LAB (FR) | 2024-01-10 | — | — | EP | disclosed |
| CN-111936499-B | Heterobicyclic inhibitors of MAT2A and methods for treating cancer | 法国施维雅药厂 | 2023-09-19 | — | — | CN | disclosed |
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | SERVIER PHARMACEUTICALS LLC (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210115045-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | SERVIER PHARMACEUTICALS LLC | 2021-04-22 | — | — | US | disclosed |
| US-10961266-B2 | Chemoselective methylene hydroxylation in aromatic molecules | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3774805-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | Agios Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-111936499-A | Heterobicyclic inhibitors of MAT2A and methods for treating cancer | 安吉奥斯医药品有限公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20200087331-A1 | CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-03-19 | — | — | US | disclosed |
| WO-2019191470-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20130060050-A1 | PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-07 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20110124884-A1 | PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| EP-2246343-A1 | PROCESS FOR PRODUCTION OF THIOPHENE COMPOUND AND INTERMEDIATE THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-5091416-A | INSECTICIDAL COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-25 | — | — | US | disclosed |
| US-5026727-A | 1,1-Difluoro-2-alkyl-2-(4-trifluoromethoxy-phenyl)-3-(substituted benzyloxy) propane | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-25 | — | — | US | disclosed |
| EP-0361694-A2 | Insecticidal compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-04-04 | — | — | EP | disclosed |
| EP-0361695-A2 | Insecticidal compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060050-A1 | PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF | SULT1E1, CYP3A4, TKT | MEN1 3326/4885KMT2A 2284/4885SMN1; SMN2 4643/4885 |
| US-10961266-B2 | Chemoselective methylene hydroxylation in aromatic molecules | PAH, DBH, AHR | MEN1 1627/4885KMT2A 746/4885SMN1; SMN2 2130/4885 |
| US-20210115045-A1 | HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | MEN1 1001/4885KMT2A 189/4885SMN1; SMN2 1469/4885 |
| US-20200087331-A1 | CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES | PAH, DBH, AHR | MEN1 1627/4885KMT2A 746/4885SMN1; SMN2 2130/4885 |
| US-20110124884-A1 | PROCESS FOR PRODUCING THIOPHENE COMPOUND AND INTERMEDIATE THEREOF | TST, SULT1E1, GRHPR | MEN1 4668/4885KMT2A 921/4885SMN1; SMN2 4842/4885 |
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | MEN1 738/4885KMT2A 3064/4885SMN1; SMN2 4692/4885 |
| US-11524960-B2 | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | MAT2A, MAT2B, MAT1A | MEN1 1001/4885KMT2A 189/4885SMN1; SMN2 1469/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | MEN1 1770/4885KMT2A 262/4885SMN1; SMN2 534/4885 |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | PC, ACACA, PCCA | MEN1 3894/4885KMT2A 3289/4885SMN1; SMN2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.